Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity

FEBS Journal

Volumn 280, Issue 24, 2013, Pages 6498-6507

  Leão, Mariana ^a   Gomes, Sara ^a   Soares, Joana ^a   Bessa, Cláudia ^a   MacIel, Cláudia ^a   Ciribilli, Yari ^b   Pereira, Clara ^a   Inga, Alberto ^b   Saraiva, Lucília ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF TRENTO   (Italy)

Author keywords

actin; p53; p53 MDMX interaction; screening assays; yeast

Indexed keywords

ACTIN; MESSENGER RNA; NUTLIN 3; PIFITHRIN ALPHA; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

ACTIN FILAMENT; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL MEMBRANE; CONTROLLED STUDY; DEPOLARIZATION; FUNGAL CELL; FUNGAL DETECTION; FUNGAL STRAIN; FUNGUS GROWTH; GENE TARGETING; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; YEAST;

ACTIN; P53; P53-MDMX INTERACTION; SCREENING ASSAYS; YEAST;

ACETATES; ACTINS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LUCIFERASES; MUTATION; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PYRAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SACCHAROMYCES CEREVISIAE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84889663663     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12552     Document Type: Article

References (22)

1. Pei D, Zhang Y, &, Zheng J, (2012) Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget 3, 228-235.
2. Shadfan M, Lopez-Pajares V, &, Yuan ZM, (2012) MDM2 and MDMX: alone and together in regulation of p53. Transl Cancer Res 1, 88-89.
3. Wade M, Li YC, &, Wahl GM, (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13, 83-96.
4. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al,. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848.
5. Wade M, &, Wahl GM, (2009) Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7, 1-11.
6. Vassilev LT, (2005) p53 activation by small molecules: application in oncology. J Med Chem 48, 4491-4499.
7. Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, et al,. (2010) Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 285, 10786-10796.
8. Bista M, Smithson D, Pecak A, Salinas G, Pustelny K, Min J, Pirog A, Finch K, Zdzalik M, Waddell B, et al,. (2012) On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53. PLoS ONE 7, e37518.
9. Pereira C, Leão M, Soares J, Bessa C, &, Saraiva L, (2012) New therapeutic strategies for cancer and neurodegeneration emerging from yeast cell-based systems. Curr Pharm Des 18, 4223-4235.
10. Pereira C, Coutinho I, Soares J, Bessa C, Leão M, &, Saraiva L, (2012) New insights into cancer-related proteins provided by the yeast model. FEBS J 279, 697-712.
11. Leão M, Pereira C, Bisio A, Ciribilli Y, Paiva AM, Machado N, Palmeira A, Fernandes MX, Sousa E, Pinto M, et al,. (2013) Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach. Biochem Pharmacol 85, 1234-1245.
12. Andreotti V, Ciribilli Y, Monti P, Bisio A, Lion M, Jordan J, Fronza G, Menichini P, Resnick MA, &, Inga A, (2010) p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system. PLoS ONE 6, e20643.
13. Coutinho I, Pereira C, Pereira G, Gonçalves J, Côrte-Real M, &, Saraiva L, (2011) Distinct regulation of p53-mediated apoptosis by protein kinase Cα, δ, ε and ζ: evidence in yeast for transcription-dependent and -independent p53 apoptotic mechanisms. Exp Cell Res 317, 1147-1158.
14. Gudkov AV, &, Komarova EA, (2005) Prospective therapeutic applications of p53 inhibitors. Biochem Biophys Res Commun 331, 726-736.
15. Maslon MM, &, Hupp TR, (2010) Drug discovery and mutant p53. Trends Cell Biol 20, 542-555.
16. Schärer E, &, Iggo R, (1992) Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res 20, 1539-1545.
17. Inga A, &, Resnick MA, (2001) Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants. Oncogene 20, 3409-3419.
18. Arava Y, (2003) Isolation of polysomal RNA for microarray analysis. Methods Mol Biol 224, 79-87.
19. Sagot I, Pinson B, Salin B, &, Daignan-Fornier B, (2006) Actin bodies in yeast quiescent cells: an immediately available actin reserve? Mol Biol Cell 17, 4645-4655.
20. Comer KA, Dennis PA, Armstrong L, Catino JJ, Kastan MB, &, Kumar CC, (1998) Human smooth muscle α-actin gene is a transcriptional target of the p53 tumor suppressor protein. Oncogene 16, 1299-1308.
21. Secchiero P, Rimondi E, Di Lasio MG, Voltan R, Gonelli A, &, Zauli G, (2012) Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages. J Cell Physiol 227, 1829-1837.
22. Heng YW, &, Koh CG, (2010) Actin cytoskeleton dynamics and the cell division cycle. Int J Biochem Cell Biol 42, 1622-1633.